Temozolomide after radiotherapy improves glioma survival

Bookmark and Share
Published: 3 Jun 2016
Views: 3088
Dr Martin Van Den Bent - Erasmus MC Cancer Center, Rotterdam, The Netherlands

Dr Van Den Bent presents at ASCO 2016 about the phase III trial, which showed that patients with anaplastic glioma without 1p/19q co-deletion benefit from adjuvant chemotherapy, according to early results from a European phase III trial.

Read the news story and watch the video interview for more.